

Version 3.4      Revision Date: 09.04.2021      SDS Number: 22145-00016      Date of last issue: 25.09.2020  
Date of first issue: 15.10.2014

---

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Human Chorionic Gonadotropin Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person  
responsible for the SDS : EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

215-631-6999

---

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A	H360Fd: May damage fertility. Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 1	H372: Causes damage to organs through prolonged or repeated exposure.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360Fd May damage fertility. Suspected of damaging the unborn child.  
H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P260 Do not breathe dust.

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

P264 Wash skin thoroughly after handling.  
 P270 Do not eat, drink or smoke when using this product.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Gonadotropin, chorionic

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Gonadotropin, chorionic	9002-61-3 232-660-2	Repr. 1A; H360Fd STOT RE 1; H372 (Ovary)	>= 90 - <= 100

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

- Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks : May damage fertility. Suspected of damaging the unborn child.  
Causes damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Sulphur oxides

**5.3 Advice for firefighters**

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- Specific extinguishing meth- : Use extinguishing measures that are appropriate to local cir-

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

ods cumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Avoid contact with eyes.

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Do not eat, drink or smoke when using this product.  
 Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

**7.2 Conditions for safe storage, including any incompatibilities**

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
 Strong oxidizing agents  
 Organic peroxides  
 Explosives  
 Gases

**7.3 Specific end use(s)**

Specific use(s) : No data available

**SECTION 8: Exposure controls/personal protection****8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Gonadotropin, chorionic	9002-61-3	TWA	OEB 4 (3 µg/m <sup>3</sup> )	Internal
		Wipe limit	25 µg/100 cm <sup>2</sup>	Internal

**8.2 Exposure controls****Engineering measures**

Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Personal protective equipment**

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

Eye protection	:	Wear the following personal protective equipment: Safety goggles
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	:	Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	:	powder
Colour	:	off-white
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available

# SAFETY DATA SHEET



## Human Chorionic Gonadotropin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

Relative density	:	No data available
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

### 10.4 Conditions to avoid

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

May damage fertility. Suspected of damaging the unborn child.

**Components:****Gonadotropin, chorionic:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Intravenous injection  
Fertility: LOAEL: 8,89 mg/kg body weight  
Result: Effects on fertility

Test Type: Fertility  
Application Route: Intraperitoneal injection  
Fertility: LOAEL: 0,883 mg/kg body weight  
Result: Effects on fertility

Test Type: Fertility  
Species: Monkey  
Fertility: LOAEL: 0,224 mg/kg body weight  
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Hamster  
Application Route: Intraperitoneal injection  
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight  
Result: Embryo-foetal toxicity

Reproductive toxicity - Assessment : Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies., Some evidence



## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Causes damage to organs through prolonged or repeated exposure.

**Components:****Gonadotropin, chorionic:**

Target Organs	:	Ovary
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Gonadotropin, chorionic:**

Inhalation	:	Target Organs: ovaries Symptoms: effects on menstruation, gynecomastia, Head-ache, mental depression, Irritability, restlessness, Fatigue
------------	---	--

---

**SECTION 12: Ecological information****12.1 Toxicity**

No data available

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential**

No data available

**12.4 Mobility in soil**

No data available

**12.5 Results of PBT and vPvB assessment****Product:**

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

**12.6 Other adverse effects****Product:**

Endocrine disrupting potential	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to
--------------------------------	---	---

---

# SAFETY DATA SHEET



## Human Chorionic Gonadotropin Formulation



Version 3.4      Revision Date: 09.04.2021      SDS Number: 22145-00016      Date of last issue: 25.09.2020  
Date of first issue: 15.10.2014

---

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

- Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.
- 

### SECTION 14: Transport information

#### 14.1 UN number

Not regulated as a dangerous good

#### 14.2 UN proper shipping name

Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

#### 14.4 Packing group

Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H360Fd : May damage fertility. Suspected of damaging the unborn child.  
 H372 : Causes damage to organs through prolonged or repeated exposure.

**Full text of other abbreviations**

Repr. : Reproductive toxicity  
 STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

# SAFETY DATA SHEET



## Human Chorionic Gonadotropin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.4	09.04.2021	22145-00016	Date of first issue: 15.10.2014

---

**Classification of the mixture:**

Repr. 1A  
STOT RE 1

H360Fd  
H372

**Classification procedure:**

Calculation method  
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN